Cargando…
The effect of spinal cord-injury level on the outcome of neurogenic bladder treatment using OnabotulinumtoxinA
AIM: The aim was to report the effectiveness and safety OnabotulinumtoxinA (Botox, Allergan, Inc., Irvine, CA, USA) intradetrusor injections in spinal cord-injured (SCI) patients with refractory neurogenic detrusor overactivity. And to assess the result based on SCI level. MATERIALS AND METHODS: We...
Autores principales: | Al Taweel, Waleed, Alzyoud, Khalil Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518367/ https://www.ncbi.nlm.nih.gov/pubmed/26229318 http://dx.doi.org/10.4103/0974-7796.152013 |
Ejemplares similares
-
OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012) -
Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014) -
Neurogenic bladder in spinal cord injury patients
por: Taweel, Waleed Al, et al.
Publicado: (2015) -
Reduction in Bladder-Related Autonomic Dysreflexia after OnabotulinumtoxinA Treatment in Spinal Cord Injury
por: Fougere, Renée J., et al.
Publicado: (2016) -
OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)